NYSE:LLY

Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC

SUZHOU, China, Jan. 13, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced...

2020-01-13 12:42 6548

Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®

- Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease - Alliance to continue to include three product families – empagliflozin, linagliptin and insulin glargine INGELHEIM, Germany, and INDIANAPOLIS,...

2019-11-04 22:00 2973

American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway

INGELHEIM, Germany and INDIANAPOLIS, Ind., Nov. 27, 2018  /PRNewswire/ -- A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in a...

2018-11-27 15:00 2889

European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis

INDIANAPOLIS, Feb. 14, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Commission has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets inEurope for the treatment of moderate...

2017-02-14 06:27 1897

Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting

INDIANAPOLIS, Dec. 9, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today presented detailed results of its phase 3 EXPEDITION3 trial at the 9th Clinical Trials on Alzheimer's Disease (CTAD) meeting. As previously disclosed, solanezumab did not meet the primary endpoint in the EXPEDITION3...

2016-12-09 10:15 2112

Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial

INDIANAPOLIS, Nov. 23, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD). Patients treated with s...

2016-11-23 19:59 1246

Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs

INDIANAPOLIS, June 9, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology (EULAR 2016) inLondon. The findings d...

2016-06-09 18:45 1685

Patient-reported Outcomes across Phase 3 studies of Baricitinib demonstrate Statistically Significant Improvements in Physical Function and Quality of Life Symptoms in Patients with Rheumatoid Arthritis (RA)

INDIANAPOLIS, June 9, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that in two phase 3 trials patients with rheumatoid arthritis (RA) treated with baricitinib reported significant improvements in quality of life symptoms and other p...

2016-06-09 18:45 1543

Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016)

INDIANAPOLIS, June 7, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and patient-reported outcomes data from baricitinib's phase 3 global studies will be presented, along with other phase 2...

2016-06-07 19:00 1665

Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis

INDIANAPOLIS, Nov. 9, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced detailed data from pivotal phase 3 study RA-BEAM, the fourth successful phase 3 study of baricitinib, at the American College of Rheumatology/Association ...

2015-11-09 10:08 1630

Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate

INDIANAPOLIS, Nov. 9, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce detailed data from the pivotal phase 3 RA-BEGIN study, which show investigational baricitinib alone and in combination were superior to methotrexate monoth...

2015-11-09 09:49 1553

Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis

INDIANAPOLIS, Sept. 29, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with mod...

2015-09-29 18:45 1733

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries

INDIANAPOLIS and INGELHEIM, Germany, Oct. 29, 2014 /PRNewswire/ -- In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are changing the operational and financial structur...

2014-10-29 20:00 1254

Lilly and Alzheimer's Disease International Partner to Address Barriers that Impact the Accurate and Timely Diagnosis of Alzheimer's Disease

-- New educational resources to help patients and caregivers communicate vital information with physicians are released as global leaders meet to discuss the global burden of Alzheimer's disease INDIANAPOLIS, June 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Alzheimer's Disease Int...

2014-06-12 15:00 1752

Lilly Releases Report on Corporate Responsibility Efforts

-- Company communicates progress on numerous indicators of economic, environmental, and social performance INDIANAPOLIS, Dec. 6, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has released its 2012-13 Corporate Responsibility Report( http://www.lilly.com/Documents/Lilly_2012_2013_CRreport.p...

2013-12-06 06:12 9336

Amyvid (Florbetapir (18F)) Solution for Injection Approved in European Union for Use in Patients with Cognitive Impairment Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Impairment

Amyvid is the first and only PET imaging agent approved to measure beta-amyloid neuritic plaque density in the living brain INDIANAPOLIS, Jan. 16, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the E...

2013-01-16 04:06 1273

Lilly Releases Update on Corporate Responsibility Efforts

Company communicates progress on numerous indicators of economic, environmental and social performance INDIANAPOLIS, Dec. 3, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has released its 2011/2012 Corporate Responsibility Update (www.lilly.com/Documents/Lilly_2011_2012_CRupdate.pdf). Th...

2012-12-03 20:00 1250

European Commission Approves Cialis for the Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia

Cialis becomes the first and only medication approved in the EU for both the signs and symptoms of benign prostatic hyperplasia and erectile dysfunction INDIANAPOLIS, Oct. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved Cialis(R) ...

2012-10-30 21:39 1013

ALIMTA(R) Label Update Approved by European Commission to Reflect Significant Overall Survival Benefits for Specific Lung Cancer Patients

INDIANAPOLIS, Oct. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved an update to the label for ALIMTA(R) (pemetrexed for injection), adding final overall survival data to the continuation maintenance indication for patients with adv...

2012-10-30 21:22 931

Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient(R) (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure

Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population INDIANAPOLIS and TOKYO, Aug. 27, 2012 /PRNewswire-Asia/ -- Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) today announced data from the TRIL...

2012-08-27 08:07 1303